JP Morgan Maintains Overweight on Elevance Health, Lowers Price Target to $552
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill has maintained an Overweight rating on Elevance Health (NYSE:ELV) but reduced the price target from $569 to $552.
November 17, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Elevance Health's stock may experience a slight negative impact due to JP Morgan lowering its price target, despite maintaining an Overweight rating.
A reduction in price target by a major analyst like JP Morgan can create a negative sentiment among investors, potentially leading to a short-term decline in the stock price. However, the impact may be mitigated by the fact that the Overweight rating was reaffirmed, indicating continued confidence in the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100